Compare LQDA & MTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | MTG |
|---|---|---|
| Founded | 2004 | 1957 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.3B |
| IPO Year | 2020 | 2008 |
| Metric | LQDA | MTG |
|---|---|---|
| Price | $91.70 | $30.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 4 |
| Target Price | ★ $41.00 | $28.50 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.06% |
| EPS Growth | ★ 51.81 | 8.65 |
| EPS | 0.52 | ★ 1.62 |
| Revenue | $158,320,000.00 | ★ $1,213,636,000.00 |
| Revenue This Year | $278.87 | $2.50 |
| Revenue Next Year | $57.13 | $1.77 |
| P/E Ratio | $173.50 | ★ $18.81 |
| Revenue Growth | ★ 1031.18 | 0.49 |
| 52 Week Low | $21.15 | $24.69 |
| 52 Week High | $91.57 | $31.89 |
| Indicator | LQDA | MTG |
|---|---|---|
| Relative Strength Index (RSI) | 67.21 | 61.63 |
| Support Level | $31.99 | $25.54 |
| Resistance Level | N/A | $31.89 |
| Average True Range (ATR) | 5.09 | 0.77 |
| MACD | 0.15 | -0.06 |
| Stochastic Oscillator | 99.45 | 52.98 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
MGIC Investment Corp provides private mortgage insurance, other mortgage credit risk management solutions, and ancillary services. The insurance premiums that these customers pay for the protection account for close to the majority of the company's total revenue. Investment income accounts for the remaining revenue. The company sells its insurance products in all states of the United States and in Puerto Rico. Its greatest exposure is in California, Florida, Texas, Pennsylvania, Ohio, Illinois, Virginia, North Carolina, Georgia, and New York.